



Cite this: *RSC Adv.*, 2024, 14, 8921

Synthesis of 1,2,3-triazole-piperazin-benzo[*b*][1,4]thiazine 1,1-dioxides: antibacterial, hemolytic and *in silico* TLR4 protein inhibitory activities†

Nagavelli Ramu,^a Thupurani Murali Krishna,^b Ravikumar Kapavarapu^c and Sirassu Narsimha ^{*a}

In this study, we designed and synthesized a number of novel 1,2,3-triazole-piperazin-benzo[*b*][1,4]thiazine 1,1-dioxide derivatives and investigated their *in vitro* antibacterial and hemolytic activity. When compared to the lead chemical, dicloxacillin, the majority of the compounds demonstrated acceptable activity. Among them, the most promising compounds **6e**, **6g**, **6i**, **8d**, and **8e** exhibited excellent antibacterial activity against the methicillin-susceptible *S. aureus* (MSSA), methicillin-resistant *S. aureus* (MRSA), and vancomycin-resistant *S. aureus* (VRSA) with MIC values of 1.56 ± 0.22 to $12.5 \pm 1.75 \mu\text{g mL}^{-1}$, respectively. The percentage of hemolysis ranged from $21.3 \mu\text{g mL}^{-1}$ to $33.8 \mu\text{g mL}^{-1}$. Out of the six compounds (**6i**, **6e**, **6f**, **6g**, **8e**, **8d**) tested compound **8e** and **8d** displayed minimal or negligible hemolytic activity across all the tested concentrations 29.6% and 30.2% recorded at $100 \mu\text{g mL}^{-1}$ concentration respectively. *In silico* docking studies were performed to evaluate the molecular interactions of **6e**, **6f**, **6g**, **6i**, **8d**, and **8e** compounds with Human, Mouse and Bovine TLR4 proteins (PDB: 3FXI, 3VQ1, 3RG1) and observed that three of the compounds (**6i**, **8d**, and **8i**) had appreciable binding energies ranging from -8.5 to $-9.0 \text{ Kcal mol}^{-1}$. Finally, the *in silico* pharmacokinetic profile was predicted for potent compounds **8d**, **8e** and **6i** using SWISS/ADME. All compounds investigated in this study adhered to Lipinski's rule of five with slight deviation in molecular weight (**8d** and **8e**).

Received 3rd November 2023
Accepted 3rd March 2024

DOI: 10.1039/d3ra07509e

rsc.li/rsc-advances

Introduction

Overuse of currently available antibiotics, efflux mechanisms of bacteria, genetic modifications or mutations leads to the development of Multi-Drug Resistance (MDR) bacterial strains. One of the most important bacteria is *Staphylococcus aureus*, which has evolved and developed resistance to various antibiotics. Bacterial infections, a serious public health concern,¹ have recently caused a huge increase in fatalities globally. On the other hand, the introduction of new antibiotics has decreased dramatically during the last decade. Thus, the discovery or creation of antimicrobial medicines with diverse chemical structures is critical for the treatment of bacterial infections and the consequent reduction of clinical drug resistance. Indeed, the World Health Organization (WHO) has warned that all known antibiotics may become ineffective

against common pathogens in the near future, potentially leading to untreatable infections. As a result, there is an urgent need for global scientists to continue their efforts in the discovery and development of novel antibacterial agents with effective therapeutic activity.²

The importance of testing a medicine for its property of hemolysis cannot be understated, as it relates directly to the safety and efficacy of the medication.^{3,4} Hemolysis refers to the rupture or destruction of red blood cells, and this can have serious consequences for a patient's health. There are several reasons why testing for hemolysis is crucial in the development and use of medicines.⁵ The foremost concern in medicine development and administration is patient safety. Hemolysis can lead to severe health complications, including anemia, organ damage, and even death. Testing for hemolysis ensures that a medication does not pose a risk to a patient's blood cells.⁶ Hemolysis can also affect the effectiveness of a medicine. If a medication causes the destruction of red blood cells, it may hinder the body's ability to transport oxygen and nutrients to vital organs and tissues. Therefore, testing for hemolysis helps ensure that the drug remains effective in treating the targeted condition.⁷

Understanding a drug's potential for hemolysis is essential for determining the appropriate dosage. Medications that have a higher risk of causing hemolysis may need to be administered

^aDepartment of Chemistry, Chaitanya Deemed to be University, Hyderabad, Telangana, India. E-mail: narsimha.s88@gmail.com; narsimha.s88@chaitanya.edu.in

^bDepartment of Biotechnology, Chaitanya Deemed to be University, Hyderabad, Telangana, India

^cDepartment of Pharmaceutical Chemistry and Phytochemistry, Nirmala College of Pharmacy, Atmakur, Mangalgi, Andhra Pradesh, India

† Electronic supplementary information (ESI) available. See DOI: <https://doi.org/10.1039/d3ra07509e>


at lower doses or with specific precautions to minimize the risk to patients.⁸ Hemolysis-induced adverse reactions can be life-threatening. By identifying drugs that have the potential to cause hemolysis during the testing phase, healthcare providers can make informed decisions about whether to prescribe them and monitor patients more closely when necessary.⁹ Regulatory agencies, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), require thorough testing of new medications, including assessments of their potential to cause hemolysis. Compliance with these regulations is crucial for gaining approval to market a drug.¹⁰ Toll-like receptor 4 (TLR4) is a member of the pattern recognition receptor family, which is important for the human defence system and has a very sensitive and selective response to invasive pathogens.¹¹ Numerous medications that target TLR4 are currently undergoing clinical trials, and the two FDA-approved medications, monophosphoryl lipid A (MPLA) for the treatment of bladder and cervical cancer and Bacillus Calmette-Guerin, a vaccine against tuberculosis, are readily available.¹²

Because of their synthesis and fascinating pharmacological properties, 1,2,3-triazoles and their hybrids have emerged as "lead molecules" in drug discovery in recent years.^{13–16} As antibacterial agents, various 1,2,3-triazole-based compounds have been synthesized.¹⁷ In contrast, Fig. 1 shows a few commercially available medicines with 1,2,3-triazole containing Tazobactam and Cefatrizine are potent antibiotics.^{18,19} Similarly, sulfones are valuable synthetic intermediates for the construction of chemically and biologically important molecules.^{20–22} Aromatic sulfones have wide application in therapeutic study particularly as antipsychotic agents.²³ Very recently, we have developed an efficient method for the synthesis of a novel class of 1,2,3-triazole containing sulfonyl derivatives.^{24–31} Based on the previous reports, we envisaged that the synthesized 1,2,3-triazole as well as their sulfone derivatives might show potent antibacterial (Fig. 1) hemolytic and *in silico* TLR4 protein inhibitory activities.

In view of the (i) significant roles of 1,2,3-triazoles, sulfonyl, and benzo[*b*][1,4]thiazine in the development of several anti-bacterial compounds, (ii) application of molecular hybridization approaches to access potent biologically active compounds, and (iv) in continuation of research work on the synthesis and biological evaluation of 1,2,3-triazole-based compounds. Herein, we planned to synthesize some new 1,2,3-triazole-piperazin-benzo[*b*][1,4]thiazine 1,1-dioxides and evaluated for their antibacterial, hemolytic and *in silico* TLR-4 protein inhibitory activities.

Results and discussion

The synthesis of the title compounds is as outlined in Scheme 1. 2*H*-benzo[*b*][1,4]thiazin-3(4*H*)-one (1) in reaction with PCl₅ in reflux condition yields the corresponding 3-chloro-2*H*-benzo[*b*][1,4]thiazine (2). Oxidation of compound 2 with 3-chlorobenzoperoxoic acid (*m*-CPBA) in dichloromethane at room temperature resulted in the formation of 3-chloro-2*H*-benzo[*b*][1,4]thiazine 1,1-dioxide (3). Compounds 3 further reacted with 1-(prop-2-yn-1-yl)piperazine in dioxane in presence of triethyl amine to obtain key intermediate 3-(4-(prop-2-yn-1-yl)piperazin-1-yl)-2*H*-benzo[*b*][1,4]thiazine 1,1-dioxide (4).³²

The 1,3-dipolar cycloaddition of terminal alkyne 4 with various aryl azides (5a–5j) using a catalytic amount of copper iodide at room temperature provided the corresponding 1,2,3-triazole-piperazin-benzo[*b*][1,4]thiazine 1,1-dioxide (6a–6j) in good to excellent yields.³³ Similarly, the alkyne 4 with different aryl sulfonyl azides (7a–7g) using catalytic amount of copper iodide at 60 °C temperature for 10–12 h to form corresponding sulfonyl 1,2,3-triazole-piperazin-benzo[*b*][1,4]thiazine 1,1-dioxide (8a–8g) in good to excellent yields (Scheme 2).²⁷

Antibacterial activity

The minimum inhibitory concentration (MIC) of the title compounds (6a–6j & 8a–8g) was determined by using the standard broth microdilution technique against three *Staphylococcus*






Fig. 1 Design strategy for synthesis of 1,2,3-triazole-piperazin-benzo[*b*][1,4]thiazine 1,1-dioxides via molecular hybridization approach.





Scheme 1 Reagents and conditions: (a) PCl_5 , reflux $180\text{ }^\circ\text{C}$, 1 h; (b) *m*-CPBA, DCM, $0\text{--}5\text{ }^\circ\text{C}$, 2 h; (c) 1-(prop-2-yn-1-yl)piperazine, TEA, dioxane, $80\text{ }^\circ\text{C}$, 8 h.



Scheme 2 Synthesis of 1,2,3-triazole-piperazin-benzo[b][1,4]thiazine 1,1-dioxide (**6a–6j** & **8a–8g**).

aureus mutant strains: methicillin-susceptible *S. aureus* (MSSA), methicillin-resistant *S. aureus* (MRSA), and vancomycin-resistant *S. aureus* (VRSA).²⁴ The MIC result was displayed as $\mu\text{g mL}^{-1}$ (Table 1). Table 1 shows that among the examined chemicals, **6e**, **6f**, **6g**, **6i**, **8d**, and **8e** had substantial MIC values against all of the mutant strains tested, with MICs ranging from 1.56 to $12.5\text{ }\mu\text{g mL}^{-1}$.

Among the tested series, compound **8e**, which contains a 4-fluorophenyl sulfonyl group on the 1,2,3-triazole ring, showed significantly superior inhibiting activity than the standard dicloxacillin against three tested strains, *S. aureus* (MSSA) ($1.56\text{ }\mu\text{g mL}^{-1}$) \approx 2 fold more potent as compared to the standard ($3.12\text{ }\mu\text{g mL}^{-1}$), *S. aureus* (MRSA) ($1.56\text{ }\mu\text{g mL}^{-1}$) \approx 4 fold more potent as compared to the standard ($6.25\text{ }\mu\text{g mL}^{-1}$), and *S. aureus* (VRSA) ($3.12\text{ }\mu\text{g mL}^{-1}$) \approx 2 fold more potent as compared to the standard ($6.25\text{ }\mu\text{g mL}^{-1}$). Also, compounds **8d** (4-chlorophenyl sulfonyl group on the 1,2,3-triazole) and **6i** (4-fluorophenyl group on the 1,2,3-triazole) showed significantly greater inhibiting activity than the standard against *S. aureus* (MSSA) ($1.56\text{ }\mu\text{g mL}^{-1}$) \approx 2 fold more potent, *S. aureus* (MRSA) ($3.12\text{ }\mu\text{g mL}^{-1}$) \approx 2 fold more potent as compared to the standard ($6.25\text{ }\mu\text{g mL}^{-1}$), and equipotent activity against *S. aureus* (VRSA) ($6.25\text{ }\mu\text{g mL}^{-1}$) as compared to the standard. Compound **6e** (3,5-dichloro phenyl on triazole) have demonstrated equipotent activity against both MSSA (MIC = $3.12\text{ }\mu\text{g mL}^{-1}$) and MRSA (MIC = $6.25\text{ }\mu\text{g mL}^{-1}$) and good activity against VRSA (MIC = $12.5\text{ }\mu\text{g mL}^{-1}$) as compared to the standard dicloxacillin.

Table 1 *In vitro* antibacterial activity data of new compounds (**6a–6j** & **8a–8g**)

Compound	R	Minimum inhibitory concentration ^a (MIC)		
		MSSA	MRSA	VRSA
6a	4-Me	—	—	—
6b	3,5-diMe	50 ± 1.81	50 ± 1.75	—
6c	4-OMe	25 ± 1.22	25 ± 1.37	—
6d	3,5-diOMe	12.5 ± 1.42	12.5 ± 1.64	25 ± 1.22
6e	3,5-diOMe, 4-Cl	3.12 ± 0.48	6.25 ± 1.88	12.5 ± 1.75
6f	4-Cl	6.25 ± 1.66	12.5 ± 1.86	6.25 ± 1.27
6g	3,5-diCl	3.12 ± 0.52	6.25 ± 1.37	6.25 ± 1.44
6h	4-Br	12.5 ± 1.15	25 ± 1.12	25 ± 1.54
6i	4-F	1.56 ± 0.32	3.12 ± 0.46	6.25 ± 1.12
6j	4-NO ₂	25 ± 1.66	50 ± 1.78	50 ± 1.82
8a	4-Me	25 ± 1.87	25 ± 1.45	—
8b	4-OMe	12.5 ± 1.25	25 ± 1.39	25 ± 1.71
8c	4-Br	6.25 ± 1.24	12.5 ± 1.15	25 ± 1.51
8d	4-Cl	1.56 ± 0.56	3.12 ± 0.32	6.25 ± 0.63
8e	4-F	1.56 ± 0.22	1.56 ± 0.35	3.12 ± 0.51
8f	4-NO ₂	12.5 ± 0.92	25 ± 1.12	25 ± 1.02
8g	4-CN	12.5 ± 0.88	25 ± 1.10	25 ± 1.11
Standard	Dicloxacillin	3.12 ± 0.12	6.25 ± 0.24	6.25 ± 0.41

^a MIC: *i.e.*, the lowest concentration of the test compound to inhibit the growth of bacteria. Values are expressed as mean \pm SD, “—” indicates concentration $> 50\text{ }\mu\text{g mL}^{-1}$.




Fig. 2 The percentage of hemolysis of the tested compounds (6i, 6e, 6f, 6g, 8e & 8d).

Similarly, compound **6f** (4-chlorophenyl group on the 1,2,3-triazole) have shown good activity against MSSA (MIC = 6.25 $\mu\text{g mL}^{-1}$) and MRSA (MIC = 12.5 $\mu\text{g mL}^{-1}$), and equipotent activity against VRSA (MIC = 6.25 $\mu\text{g mL}^{-1}$) as compared to the standard. Remaining compounds are moderate to poor activity to poor activity with MIC values ranging from 6.25 to 50 $\mu\text{g mL}^{-1}$.

Hemolytic activity

Antimicrobial drug hemolytic activity is a crucial factor in determining how safe they are and whether they have the potential to be used in therapeutic settings.³⁴ The hemolytic assay was used in the current investigation to evaluate how the synthesized compounds affected red blood cells (RBCs). The hemolytic activities of the different concentrations (0.75 $\mu\text{g mL}^{-1}$ to 100 $\mu\text{g mL}^{-1}$) of **6i**, **6e**, **6f**, **6g**, **8e**, **8d** was determined using

human red blood corpuscles (RBCs). The hemolytic percentage of hemolysis was observed and recorded at each concentration of the test compound.

The percentage of hemolysis was ranged from 21.3 $\mu\text{g mL}^{-1}$ to 33.8 $\mu\text{g mL}^{-1}$. Out of six compounds (**6i**, **6e**, **6f**, **6g**, **8e**, **8d**) tested compound **8e** and **8d** displayed minimal or negligible hemolytic activity across all the tested concentrations 29.6% and 30.2% recorded at 100 $\mu\text{g mL}^{-1}$ concentration respectively. Following, compound **6i** and **6e** are also exhibited minimal hemolysis percentage 31.5% and 32.4% recorded at 100 $\mu\text{g mL}^{-1}$ concentration respectively. Comparing to hemolytic percentage of compounds **8e**, **8d**, **6i** and **6e**, the hemolytic percentage of compounds **6f** and **6g** were found greater with 32.8% and 33.8% recorded at 100 $\mu\text{g mL}^{-1}$ concentrations respectively. The percentage of hemolysis of the tested compounds was represented in Fig. 2.



Table 2 Molecular interaction summary of top compound with different TLR4 proteins

Compounds	Target protein	B.E (kcal mol ⁻¹)	Interacting amino acids	Nature of interactions
8d	Human TLR4	−9.0	SER183, SER184, LYS230, ASP181, HIS179, LEU212, SER207, PHE263	H-bond, π - π T-shaped, π -alkyl, π -cation, π -anion, π -sulfur, van der Waals
8e	Human TLR4	−8.7	SER183, SER184, LYS230, ASP181, HIS179, LEU212, PHE263, SER207	H-bond, π - π T-shaped, π -alkyl, π -cation, π -anion, π -sulfur, van der Waals
6i	Human TLR4	−8.5	PHE144, ILE146, GLY147, LEU138, LEU117	H-bond, π -sigma, π -alkyl, van der Waals

Molecular docking studies

In silico docking simulation studies to evaluate the molecular interactions of **6e**, **6f**, **6g**, **6i**, **8d**, **8e** compounds were done with the Human, Mouse and Bovine TLR4 proteins with PDB ID's 3FXI, 3VQ1, 3RG1 respectively. Based on the docking simulations conducted on Human, Mouse and Bovine TLR4 proteins, it is evident that compounds **6i**, **8d**, **9c**, and **8d** exhibited superior binding affinity and interaction profiles compared to other compounds analyzed in the current *in silico* study. Compounds **6e**, **6f**, **6g**, **6i**, **8d**, and **8e** displayed affinity with high binding energy towards the human TLR4 protein compared to mouse and bovine TLR4 proteins (Table 2).

Among all, the **8d** compound is displaying highest binding energy (−9.0 Kcal mol⁻¹) with human TLR4 protein. **8d** and **8e** compounds which are structurally similar analogs with variation only in the halogen group on the 4th position of the phenyl ring, (−Cl (**8d**) and −F (**8e**)) had a very similar interaction profile. They both had three H-bonds with SER183 (**8d**: 4.29 Å, **8e**: 4.04 Å), SER184 (**8d**: 4.01 Å, **8e**: 4.09 Å) and LYS230 (**8d**: 4.26 Å, **8e**: 4.46 Å), residues where the benzothiazine −S=O group is contributing two H-bond interactions with SER183 and SER184 and the triazole nitrogen had another hydrogen bond interaction with LYS230. Pi-cation and pi-anion interactions were

exhibited by LYS230 and ASP181 whereas the HIS179 had pi-sulfur interaction with the sulfonyl group which is linking triazole and 4-Chloro phenyl groups. Pi-pi T-shaped interactions were displayed by PHE263 residue with the aromatic ring of benzothiazine 1,1 dioxide ring and the LEU212 had pi-alkyl interactions with the same aromatic ring and the surrounding binding site residues in close proximity had Vander Waals interactions. **6i** compound had three H-bonds with PHE144 (6.64 Å), ILE146 (4.97 Å), GLY147 (3.66 Å) residues through the benzothiazole −S=O group and it also displays other non-hydrogen bonded interactions like pi-sigma interactions with LEU117 and pi-alkyl interactions with LEU138 residues with the fluoro substituted aromatic phenyl group. **6i** compound had a distinct binding site in human TLR4 compared with **8d** and **8e** compounds. **8d** and **8e** are buried deep inside the pocket whereas the **6i** is binding to the external the surface of human TLR4 protein (Table 2). Molecular interactions, binding site and the binding pose of **8d**, **8e** and **6i** were represented in the Fig. 3–6 respectively.

ADME properties

SWISS ADME webserver³⁵ (<http://www.swissadme.ch/>) had been used for the evaluation of physico-chemical, metabolism and



Fig. 3 Binding affinity plot of **6e**, **6f**, **6g**, **6i**, **8d**, and **8e** compounds with Human, Mouse and Bovine TLR4 proteins.






Fig. 4 Molecular binding modes of compounds with TLR4 proteins.




Fig. 5 2D molecular interactions of **8d**, **8e**, and **6i** compounds with the amino acid residues of the human TLR4 protein. Interactions were displayed as color coded dashed lines; green lines indicated the H-bonds.






Fig. 6 Binding site and 3D representation of the binding orientations of (A) **8d**, (B) **8e** and (C) **6i** compounds in Human TLR4 protein.

Table 3 Physico-chemical properties and drug-likeness prediction of compounds with better binding energy and interaction profile using SWISS ADME

Parameters	8d	8e	6i
Molecular weight (g mol ⁻¹)	521.01	504.56	440.49
log <i>P</i> o/w	2.24	2.01	2.30
No. of H-bond donors	0	0	0
No. of H-bond acceptors	8	9	7
Solubility	Soluble	Soluble	Soluble
TPSA (Å ²)	134.59	134.59	92.07
GI absorption	High	High	High
BBB permeation	No	No	No
P-gp substrate	Yes	Yes	Yes
Drug likeness (Lipinski)	Yes	Yes	Yes
Bioavailability score	0.55	0.55	0.55
CYP450 isoforms inhibition	CYP2C9, CYP3A4	CYP2C9, CYP3A4	CYP2C19, CYP2C9, CYP3A4

drug likeness properties of compounds which are found to be promising in the *in vitro* and *in silico* assessments.

In summary, the overall ADME predictions indicate that the compounds **8d**, **8e** and **6i** a favorable pharmacokinetic profile (Table 3). They will have high gastrointestinal (GI) absorption and none of the top compounds were predicted to permeate the blood-brain barrier (BBB) and might act as substrates for P-glycoprotein (P-gp). All of the top compounds investigated in this study adhered to Lipinski's rule of five with slight deviation in molecular weight (**8d** and **8e**). Furthermore, the compounds were also predicted to have the potential to inhibit cytochrome P450 isoforms of CYP2C9, CYP2C19 and CYP3A4.

Conclusion

In the present work, a series of novel 1,2,3-triazole-piperazin-benzo[*b*][1,4]thiazine 1,1-dioxide derivatives (**6a–6j** and **8a–8g**) and investigated them *in vitro* antibacterial against methicillin-susceptible *S. aureus* (MSSA), methicillin-resistant *S. aureus* (MRSA), and vancomycin-resistant *S. aureus* (VRSA). Among them, the compounds **6e**, **6g**, **6i**, **8d**, and **8e** exhibited excellent antibacterial activity against with MIC values of 1.56 ± 0.22 to

$12.5 \pm 1.75 \mu\text{g mL}^{-1}$, the most potent compounds (**6i**, **6e**, **6f**, **6g**, **8e**, **8d**) were tested hemolytic activity and the compounds **8e** and **8d** displayed minimal or negligible hemolytic activity across all the tested concentrations 29.6% and 30.2% recorded at $100 \mu\text{g mL}^{-1}$ concentration respectively. *In silico* docking studies were performed to evaluate the molecular interactions of most potent compounds against Human, Mouse and Bovine TLR4 proteins and observed that three of the compounds **6i**, **8d**, and **8i** had appreciable binding energies ranging -8.5 to -9.0 Kcal mol⁻¹. Remarkably, the *in silico* ADME of more potent compounds **6i**, **8d**, and **8e** were also found to be covenant with the corresponding *in vitro* activity.

Experimental

All the commercially available chemicals were utilized without of further purification. The purity of compounds was analyzed on Merck 60F254 silica gel TLC plates. Melting points were recorded on a hot stage melting point apparatus in Ernst Leitz Wetzlar, Germany, and were uncorrected. The ¹H and ¹³C NMR spectra were recorded using the Mercuryplus spectrometer (operating at 500 MHz for ¹H and 126 MHz for ¹³C), and the

chemical shifts were referenced to TMS. The ESI (electrospray ionization) mass spectra at an ionising voltage of 70 eV were obtained with the help of a Shimadzu QP5050A quadrupole-based mass spectrometer. Elemental analyses were obtained with an Elemental Analyser PerkinElmer 240 C apparatus.

Synthesis of 3-(4-(prop-2-yn-1-yl)piperazin-1-yl)-2H-benzo[b][1,4]thiazine 1,1-dioxide (4)

To a mixture of 3-chloro-2H-benzo[b][1,4]thiazine 1,1-dioxide (3) (0.012 mol) with TEA (0.035 mol) in dioxane (30 mL) was added 1-(prop-2-yn-1-yl)piperazine (0.013 mol). The reaction mixture was heated at 80 °C for 8 h. The volatiles were removed under reduced pressure. The residue was diluted with CHCl₃, washed with water and brine, and dried over Na₂SO₄. Upon removing the volatiles under reduced pressure, the crude residue was purified by chromatography on silica gel (cyclohexane–EtOAc = 8 : 2) yielding compound 4 as a pale red solid, yield 77%. mp 112–114 °C. ¹H-NMR (500 MHz, CDCl₃) δ 7.97 (d, *J* = 8.0 Hz, 1H), 7.69 (d, *J* = 8.0 Hz, 1H), 7.64–7.60 (m, 1H), 7.44–7.40 (m, 1H), 4.25 (s, 2H, SO₂–CH₂), 3.89 (d, *J* = 4.0 Hz, 2H, N–CH₂), 3.76 (t, *J* = 4.0 Hz, 4H, 2N–CH₂), 3.51 (t, *J* = 4.0 Hz, 4H, 2N–CH₂), 2.22 (t, *J* = 4.0 Hz, 1H, –CH); ¹³C-NMR (126 MHz, CDCl₃) δ 153.27, 146.52, 133.52, 132.46, 129.25, 124.65, 122.51, 73.30, 72.62, 59.10, 46.33(2C), 44.16(2C), 42.26; HRMS (*m/z*): Cal for C₁₅H₁₇N₃O₂S: [*M* + *H*]⁺ *m/z*: 304.1041, found: 304.1043.

General procedure for the synthesis of 1,2,3-triazole-piperazin-benzo[b][1,4]thiazine 1,1-dioxide (6a–6j)

To a stirred solution of alkyne (4) (1.5 mmol) and aryl azide (2.0 mmol) in THF (15 mL) was added CuI (10 mol%) and the reaction mixture was stirred at room temperature for 8–10 h. After completion of the reaction, the reaction mixture was diluted with water (15 mL) and the product was extracted with ethyl acetate (2 × 15 mL). The combined organic layer was washed with brine and dried over anhydrous Na₂SO₄. After filtration, the solvent was evaporated under vacuum and the crude product obtained was purified by column chromatography (hexane/ethyl acetate gradient) to afford the compounds 6a–6j.

3-(4-((1-(*p*-Tolyl)-1H-1,2,3-triazol-4-yl)methyl)piperazin-1-yl)-2H-benzo[b][1,4]thiazine 1,1-dioxide (6a). Pale red solid; M.p: 116–128 °C; ¹H-NMR (500 MHz, CDCl₃) δ 8.03 (s, 1H, tri-H), 7.91 (d, *J* = 8.0 Hz, 1H), 7.72 (d, *J* = 8.0 Hz, 1H), 7.66 (d, *J* = 8.0 Hz, 2H), 7.61–7.57 (m, 1H), 7.46 (d, *J* = 8.0 Hz, 2H), 7.41–7.37 (m, 1H), 5.25 (s, 2H, N–CH₂), 4.31 (s, 2H, SO₂–CH₂), 3.77 (t, *J* = 4.0 Hz, 4H, 2N–CH₂), 3.55 (t, *J* = 4.0 Hz, 4H, 2N–CH₂), 2.31 (s, 3H, –CH₃). ¹³C-NMR (126 MHz, CDCl₃) δ 153.36, 146.58, 143.09, 137.08, 136.32, 133.30, 132.29, 129.02, 128.50(2C), 124.50(2C), 123.07, 122.29, 121.05, 59.52, 49.75, 46.23(2C), 44.73(2C), 21.66. ESI-MS: 437.16 [*M* + *H*]. Anal. calcd for C₂₂H₂₄N₆O₂S: C, 60.53; H, 5.54; N, 19.25. Found: C, 60.56; H, 5.56; N, 19.22.

3-(4-((1-(3,5-Dimethylphenyl)-1H-1,2,3-triazol-4-yl)methyl)piperazin-1-yl)-2H-benzo[b][1,4]thiazine 1,1-dioxide (6b). Pale red solid; M.p: 127–129 °C; ¹H-NMR (500 MHz, CDCl₃) δ 8.05 (s, 1H, tri-H), 7.88 (d, *J* = 8.0 Hz, 1H), 7.70 (d, *J* = 8.0 Hz, 1H), 7.62–7.57 (m, 1H), 7.53 (s, 1H), 7.40–7.35 (m, 1H), 7.29 (s, 2H), 5.24 (s,

2H, N–CH₂), 4.31 (s, 2H, SO₂–CH₂), 3.76 (t, *J* = 4.0 Hz, 4H, 2N–CH₂), 3.57 (t, *J* = 4.0 Hz, 4H, 2N–CH₂), 2.37 (s, 6H, 2-CH₃). ¹³C-NMR (126 MHz, CDCl₃) δ 153.20, 146.54, 143.28, 139.84(2C), 137.40, 133.55, 132.91, 129.61, 126.37, 125.14(2C), 124.04, 122.96, 122.51, 59.51, 49.42, 46.76(2C), 44.31(2C), 21.17(2C). ESI-MS: 451.18 [*M* + *H*]. Anal. calcd for C₂₃H₂₆N₆O₂S: C, 61.31; H, 5.82; N, 18.65. Found: C, 61.35; H, 5.86; N, 18.61.

3-(4-((1-(4-Methoxyphenyl)-1H-1,2,3-triazol-4-yl)methyl)piperazin-1-yl)-2H-benzo[b][1,4]thiazine 1,1-dioxide (6c). Red solid; M.p: 123–125 °C; ¹H-NMR (500 MHz, CDCl₃) δ 8.05 (s, 1H, tri-H), 7.93 (d, *J* = 8.0 Hz, 1H), 7.77 (d, *J* = 8.0 Hz, 2H), 7.70 (d, *J* = 8.0 Hz, 1H), 7.63–7.59 (m, 1H), 7.41–7.36 (m, 1H), 7.00 (d, *J* = 8.0 Hz, 2H), 5.26 (s, 2H, N–CH₂), 4.29 (s, 2H, SO₂–CH₂), 3.85 (s, 3H, OCH₃), 3.77 (t, *J* = 4.0 Hz, 4H, 2N–CH₂), 3.56 (t, *J* = 4.0 Hz, 4H, 2N–CH₂). ¹³C-NMR (126 MHz, CDCl₃) δ 159.67, 153.43, 146.25, 143.12, 133.46, 132.36, 131.55, 129.42, 124.34, 123.53(2C), 122.51, 121.53, 114.81(2C), 59.46, 56.24, 49.46, 46.48(2C), 44.07(2C). ESI-MS: 453.16 [*M* + *H*]. Anal. calcd for C₂₂H₂₄N₆O₃S: C, 58.39; H, 5.35; N, 18.57. Found: C, 58.42; H, 5.33; N, 18.55.

3-(4-((1-(3,5-Dimethoxyphenyl)-1H-1,2,3-triazol-4-yl)methyl)piperazin-1-yl)-2H-benzo[b][1,4]thiazine 1,1-dioxide (6d). Pale red solid; M.p: 134–136 °C; ¹H-NMR (500 MHz, CDCl₃) δ 8.06 (s, 1H, tri-H), 7.93 (d, *J* = 8.0 Hz, 1H), 7.72 (d, *J* = 8.0 Hz, 1H), 7.63–7.56 (m, 1H), 7.50 (s, 2H), 7.41–7.36 (m, 1H), 6.99 (s, 1H), 5.26 (s, 2H, N–CH₂), 4.31 (s, 2H, SO₂–CH₂), 3.85 (s, 6H, 2OCH₃), 3.75 (t, *J* = 4.0 Hz, 4H, 2N–CH₂), 3.52 (t, *J* = 4.0 Hz, 4H, 2N–CH₂). ¹³C-NMR (126 MHz, CDCl₃) δ 159.06(2C), 153.31, 146.61, 143.10, 140.22, 133.23, 132.56, 129.84, 124.45, 122.82, 122.14, 110.94(2C), 106.05, 59.21, 56.17(2C), 49.13, 46.65(2C), 44.52(2C). ESI-MS: 483.17 [*M* + *H*]. Anal. calcd for C₂₃H₂₆N₆O₄S: C, 57.25; H, 5.43; N, 17.42. Found: C, 57.28; H, 5.47; N, 17.39.

3-(4-((1-(4-Chloro-3,5-dimethoxyphenyl)-1H-1,2,3-triazol-4-yl)methyl)piperazin-1-yl)-2H-benzo[b][1,4]thiazine 1,1-dioxide (6e). Pale yellow solid; M.p: 141–143 °C; ¹H-NMR (500 MHz, CDCl₃) δ 8.08 (s, 1H, tri-H), 7.91 (d, *J* = 8.0 Hz, 1H), 7.69 (d, *J* = 8.0 Hz, 1H), 7.61–7.55 (m, 1H), 7.45 (s, 2H), 7.40–7.34 (m, 1H), 5.24 (s, 2H, N–CH₂), 4.31 (s, 2H, SO₂–CH₂), 3.86 (s, 6H, 2OCH₃), 3.75 (t, *J* = 4.0 Hz, 4H, 2N–CH₂), 3.52 (t, *J* = 4.0 Hz, 4H, 2N–CH₂). ¹³C-NMR (126 MHz, CDCl₃) δ 159.12(2C), 153.26, 146.30, 143.02, 138.39, 133.50, 132.03, 129.53, 124.87, 122.87, 122.18, 118.02, 112.45(2C), 59.47, 56.49(2C), 49.15, 46.58(2C), 44.36(2C). ESI-MS: 517.13 [*M* + *H*]. Anal. calcd for C₂₃H₂₅ClN₆O₄S: C, 53.43; H, 4.87; N, 16.26. Found: C, 53.45; H, 4.90; N, 16.22.

3-(4-((1-(4-Chlorophenyl)-1H-1,2,3-triazol-4-yl)methyl)piperazin-1-yl)-2H-benzo[b][1,4]thiazine 1,1-dioxide (6f). Pale yellow solid; M.p: 120–122 °C; ¹H-NMR (500 MHz, CDCl₃) δ 8.06 (s, 1H, tri-H), 7.91 (d, *J* = 8.0 Hz, 1H), 7.77 (d, *J* = 8.0 Hz, 2H), 7.72 (d, *J* = 8.0 Hz, 1H), 7.60–7.55 (m, 1H), 7.48 (d, *J* = 8.0 Hz, 2H), 7.38–7.34 (m, 1H), 5.27 (s, 2H, N–CH₂), 4.33 (s, 2H, SO₂–CH₂), 3.78 (t, *J* = 4.0 Hz, 4H, 2N–CH₂), 3.56 (t, *J* = 4.0 Hz, 4H, 2N–CH₂). ¹³C-NMR (126 MHz, CDCl₃) δ 153.35, 146.46, 143.03, 136.38, 133.12, 132.29, 130.86, 129.87, 128.72(2C), 124.14, 122.85, 122.10(2C), 121.00, 59.68, 49.54, 46.39(2C), 44.30(2C). ESI-MS: 457.11 [*M* + *H*]. Anal. calcd for C₂₁H₂₁ClN₆O₂S: C, 55.20; H, 4.63; N, 18.39. Found: C, 55.23; H, 4.60; N, 18.36.



3-(4-((1-(3,5-Dichlorophenyl)-1H-1,2,3-triazol-4-yl)methyl)piperazin-1-yl)-2H-benzo[*b*][1,4]thiazine 1,1-dioxide (6g). Pale yellow solid; M.p: 130–132 °C; ¹H-NMR (500 MHz, CDCl₃) δ 8.10 (s, 1H, tri-H), 7.91 (d, *J* = 8.0 Hz, 1H), 7.73 (d, *J* = 8.0 Hz, 1H), 7.69 (s, 2H), 7.61–7.57 (m, 1H), 7.44–7.41 (m, 1H), 7.32 (s, 1H), 5.26 (s, 2H, N-CH₂), 4.31 (s, 2H, SO₂-CH₂), 3.79 (t, *J* = 4.0 Hz, 4H, 2N-CH₂), 3.56 (t, *J* = 4.0 Hz, 4H, 2N-CH₂). ¹³C-NMR (126 MHz, CDCl₃): δ 153.54, 146.49, 143.64, 139.63, 135.40(2C), 133.39, 132.49, 129.41, 124.50, 123.90, 122.80, 122.10(2C), 120.14, 59.22, 49.12, 46.55(2C), 44.33(2C). ESI-MS: 491.07 [M + H]. Anal. calcd for C₂₁H₂₀Cl₂N₆O₂S: C, 51.33; H, 4.10; N, 17.10. Found: C, 51.29; H, 4.13; N, 17.07.

3-(4-((1-(4-Bromophenyl)-1H-1,2,3-triazol-4-yl)methyl)piperazin-1-yl)-2H-benzo[*b*][1,4]thiazine 1,1-dioxide (6h). White solid; M.p: 144–146 °C; ¹H-NMR (500 MHz, CDCl₃) δ 8.03 (s, 1H, tri-H), 7.91 (d, *J* = 8.0 Hz, 1H), 7.70 (d, *J* = 8.0 Hz, 1H), 7.65 (d, *J* = 8.0 Hz, 2H), 7.60–7.54 (m, 1H), 7.45 (d, *J* = 8.0 Hz, 2H), 7.38–7.33 (m, 1H), 5.24 (s, 2H, N-CH₂), 4.32 (s, 2H, SO₂-CH₂), 3.76 (t, *J* = 4.0 Hz, 4H, 2N-CH₂), 3.56 (t, *J* = 4.0 Hz, 4H, 2N-CH₂). ¹³C-NMR (126 MHz, CDCl₃): δ 153.25, 146.71, 143.65, 135.46, 133.22, 132.40, 131.50(2C), 129.37, 124.06, 122.81, 122.08, 121.30(2C), 120.25, 59.23, 49.39, 46.73(2C), 44.51(2C). Anal. calcd for C₂₁H₂₁BrN₆O₂S: C, 50.30; H, 4.22; N, 16.76. Found: C, 50.26; H, 4.26; N, 16.72. HRMS (*m/z*): Cal for C₂₁H₂₁BrN₆O₂S: [M + H]⁺ *m/z*: 501.0630, found: 501.0636.

3-(4-((1-(4-Fluorophenyl)-1H-1,2,3-triazol-4-yl)methyl)piperazin-1-yl)-2H-benzo[*b*][1,4]thiazine 1,1-dioxide (6i). Red solid; M.p: 129–131 °C; ¹H-NMR (500 MHz, CDCl₃) δ 8.23 (d, *J* = 8.0 Hz, 2H), 8.10 (s, 1H, tri-H), 8.00 (d, *J* = 8.0 Hz, 2H), 7.91 (d, *J* = 8.0 Hz, 1H), 7.72 (d, *J* = 8.0 Hz, 1H), 7.65–7.61 (m, 1H), 7.44–7.41 (m, 1H), 5.29 (s, 2H, N-CH₂), 4.35 (s, 2H, SO₂-CH₂), 3.78 (t, *J* = 4.0 Hz, 4H, 2N-CH₂), 3.56 (t, *J* = 4.0 Hz, 4H, 2N-CH₂). ¹³C-NMR (126 MHz, CDCl₃): δ 160.27, 158.85, 153.35, 146.48, 143.30, 133.59, 133.07, 132.50, 129.67, 125.36, 125.25, 123.86(2C), 122.93, 122.32, 117.93, 117.58, 59.23, 49.50, 45.62(2C), 44.14(2C). Anal. calcd for C₂₁H₂₁FN₆O₂S: C, 57.26; H, 4.81; N, 19.08. Found: C, 57.21; H, 4.84; N, 19.05. HRMS (*m/z*): Cal for C₂₁H₂₁FN₆O₂S: [M + H]⁺ *m/z*: 441.1431, found: 441.1435.

3-(4-((1-(4-Nitrophenyl)-1H-1,2,3-triazol-4-yl)methyl)piperazin-1-yl)-2H-benzo[*b*][1,4]thiazine 1,1-dioxide (6j). Yellow solid; M.p: 149–151 °C; ¹H-NMR (500 MHz, CDCl₃) δ 8.43 (d, *J* = 8.0 Hz, 2H), 8.29 (d, *J* = 8.0 Hz, 2H), 8.11 (s, 1H, tri-H), 7.93 (d, *J* = 8.0 Hz, 1H), 7.75 (d, *J* = 8.0 Hz, 1H), 7.65–7.61 (m, 1H), 7.44–7.40 (m, 1H), 5.28 (s, 2H, N-CH₂), 4.35 (s, 2H, SO₂-CH₂), 3.78 (t, *J* = 4.0 Hz, 4H, 2N-CH₂), 3.56 (t, *J* = 4.0 Hz, 4H, 2N-CH₂). ¹³C-NMR (126 MHz, CDCl₃): δ 153.42, 146.73, 145.77, 143.15, 140.30, 133.31, 132.02, 129.50, 126.78(2C), 124.45, 122.81(2C), 122.26, 121.62, 59.39, 49.25, 46.72(2C), 44.28(2C). ESI-MS: 468.13 [M + H]. Anal. calcd for C₂₁H₂₁N₇O₄S: C, 53.95; H, 4.53; N, 20.97. Found: C, 53.91; H, 4.50; N, 20.99.

General procedure for the synthesis of sulfonyl 1,2,3-triazole-piperazin-benzo[*b*][1,4]thiazine 1,1-dioxide (8a–8g)

To a stirred solution of alkyne (**4**) (1.5 mmol) and aryl sulfonyl azide (2.0 mmol) in THF (15 mL) was added CuI (10 mol%) and the reaction mixture was stirred at 60 °C temperature for 10–12 h. After completion of the reaction, the reaction mixture was diluted

with water (15 mL) and the product was extracted with ethyl acetate (2 × 15 mL). The combined organic layer was washed with brine and dried over anhydrous Na₂SO₄. After filtration, the solvent was evaporated under vacuum and the crude product obtained was purified by column chromatography (hexane/ethyl acetate gradient) to afford the compounds **8a–8g**.

3-(4-((1-(Tosyl)-1H-1,2,3-triazol-4-yl)methyl)piperazin-1-yl)-2H-benzo[*b*][1,4]thiazine 1,1-dioxide (8a). White solid; M.p: 153–155 °C; ¹H-NMR (500 MHz, CDCl₃) δ 8.03 (s, 1H, tri-H), 7.91 (d, *J* = 8.0 Hz, 1H), 7.76 (d, *J* = 8.0 Hz, 2H), 7.70 (d, *J* = 8.0 Hz, 1H), 7.62–7.56 (m, 1H), 7.47 (d, *J* = 8.0 Hz, 2H), 7.39–7.35 (m, 1H), 5.25 (s, 2H, N-CH₂), 4.36 (s, 2H, SO₂-CH₂), 3.78 (t, *J* = 4.0 Hz, 4H, 2N-CH₂), 3.56 (t, *J* = 4.0 Hz, 4H, 2N-CH₂), 2.35 (s, 3H, -CH₃). ¹³C-NMR (126 MHz, CDCl₃): δ 153.54, 146.58, 143.34, 137.52, 135.72, 133.88, 132.28, 130.84, 130.08(2C), 129.02, 128.05(2C), 124.35, 122.63, 59.11, 49.57, 46.46(2C), 44.16(2C), 21.26. ESI-MS: 501.13 [M + H]. Anal. calcd for C₂₂H₂₄N₆O₄S₂: C, 52.78; H, 4.83; N, 16.79. Found: C, 52.81; H, 4.80; N, 16.75.

3-(4-((1-(4-Methoxyphenyl)sulfonyl)-1H-1,2,3-triazol-4-yl)methyl)piperazin-1-yl)-2H-benzo[*b*][1,4]thiazine 1,1-dioxide (8b). Dirty white solid; M.p: 158–160 °C; ¹H-NMR (500 MHz, CDCl₃) δ 8.01 (s, 1H, tri-H), 7.91 (d, *J* = 8.0 Hz, 1H), 7.78 (d, *J* = 8.0 Hz, 2H), 7.69 (d, *J* = 8.0 Hz, 1H), 7.63–7.59 (m, 1H), 7.44–7.40 (m, 1H), 7.00 (d, *J* = 8.0 Hz, 2H), 5.27 (s, 2H, N-CH₂), 4.38 (s, 2H, SO₂-CH₂), 3.84 (s, 3H, OCH₃), 3.75 (t, *J* = 4.0 Hz, 4H, 2N-CH₂), 3.55 (t, *J* = 4.0 Hz, 4H, 2N-CH₂). ¹³C-NMR (126 MHz, CDCl₃): δ 159.27, 153.07, 146.08, 135.39, 133.52, 132.91, 131.37, 130.19(2C), 129.67, 128.24, 124.04, 123.30, 116.04(2C), 59.06, 56.29, 49.25, 46.22(2C), 44.36(2C). ESI-MS: 517.12 [M + H]. Anal. calcd for C₂₂H₂₄N₆O₅S₂: C, 51.15; H, 4.68; N, 16.27. Found: C, 51.18; H, 4.65; N, 16.25.

3-(4-((1-(4-Bromophenyl)sulfonyl)-1H-1,2,3-triazol-4-yl)methyl)piperazin-1-yl)-2H-benzo[*b*][1,4]thiazine 1,1-dioxide (8c). White solid; M.p: 166–168 °C; ¹H-NMR (500 MHz, CDCl₃) δ 8.04 (s, 1H, tri-H), 7.91 (d, *J* = 8.0 Hz, 1H), 7.71 (d, *J* = 8.0 Hz, 1H), 7.68 (d, *J* = 8.0 Hz, 2H), 7.63–7.59 (m, 1H), 7.47 (d, *J* = 8.0 Hz, 2H), 7.42–7.39 (m, 1H), 5.24 (s, 2H, N-CH₂), 4.36 (s, 2H, SO₂-CH₂), 3.75 (t, *J* = 4.0 Hz, 4H, 2N-CH₂), 3.55 (t, *J* = 4.0 Hz, 4H, 2N-CH₂). ¹³C-NMR (126 MHz, CDCl₃): δ 153.33, 146.65, 138.88, 135.39, 133.25, 132.51, 132.04(2C), 131.52, 130.09, 129.48(2C), 128.87, 124.37, 122.36, 59.55, 49.57, 46.35(2C), 44.15(2C). ESI-MS: 565.02 [M + H]. Anal. calcd for C₂₁H₂₁BrN₆O₄S₂: C, 44.60; H, 3.74; N, 14.86. Found: C, 44.63; H, 3.71; N, 14.83.

3-(4-((1-(4-Chlorophenyl)sulfonyl)-1H-1,2,3-triazol-4-yl)methyl)piperazin-1-yl)-2H-benzo[*b*][1,4]thiazine 1,1-dioxide (8d). Pale yellow solid; M.p: 153–155 °C; ¹H-NMR (500 MHz, CDCl₃) δ 8.05 (s, 1H, tri-H), 7.93 (d, *J* = 8.0 Hz, 1H), 7.80 (d, *J* = 8.0 Hz, 2H), 7.71 (d, *J* = 8.0 Hz, 1H), 7.62–7.57 (m, 1H), 7.47 (d, *J* = 8.0 Hz, 2H), 7.40–7.36 (m, 1H), 5.26 (s, 2H, N-CH₂), 4.37 (s, 2H, SO₂-CH₂), 3.77 (t, *J* = 4.0 Hz, 4H, 2N-CH₂), 3.57 (t, *J* = 4.0 Hz, 4H, 2N-CH₂). ¹³C-NMR (126 MHz, CDCl₃): δ 153.25, 146.74, 143.26, 138.48, 135.32, 133.27, 132.39, 130.67(2C), 130.13, 129.79 (2C), 129.02, 124.58, 122.37, 59.31, 49.36, 46.85 (2C), 44.18 (2C). Anal. calcd for C₂₁H₂₁ClN₆O₄S₂: C, 48.41; H, 4.06; N, 16.13. Found: C, 48.38; H, 4.02; N, 16.15. HRMS (*m/z*): Cal for C₂₁H₂₁ClN₆O₄S₂: [M + H]⁺ *m/z*: 521.0754, found: 521.0752.



3-(4-(((1-((4-Fluorophenyl)sulfonyl)-1H-1,2,3-triazol-4-yl)methyl)piperazin-1-yl)-2H-benzo[*b*][1,4]thiazine 1,1-dioxide (8e). Pale red solid; M.p: 150–152 °C; ¹H-NMR (500 MHz, CDCl₃) δ 8.25 (d, *J* = 8.0 Hz, 2H), 8.15 (d, *J* = 8.0 Hz, 2H), 8.08 (s, 1H, tri-H), 7.92 (d, *J* = 8.0 Hz, 1H), 7.72 (d, *J* = 8.0 Hz, 1H), 7.62–7.58 (m, 1H), 7.41–7.37 (m, 1H), 5.29 (s, 2H, N-CH₂), 4.37 (s, 2H, SO₂-CH₂), 3.78 (t, *J* = 4.0 Hz, 4H, 2N-CH₂), 3.56 (t, *J* = 4.0 Hz, 4H, 2N-CH₂). ¹³C-NMR (126 MHz, CDCl₃): δ 166.57, 164.87, 153.69, 146.57, 135.05, 134.33, 133.06, 132.06, 130.18 (2C), 129.36, 128.71, 124.59, 122.27, 119.81, 119.45, 59.24, 49.58, 46.22 (2C), 44.57 (2C). Anal. calcd for C₂₁H₂₁FN₆O₄S₂: C, 49.99; H, 4.20; N, 16.66. Found: C, 49.95; H, 4.17; N, 16.62. HRMS (*m/z*): Cal for C₂₁H₂₁FN₆O₄S₂: [*M* + *H*]⁺ *m/z*: 505.1050, found: 521.1053.

3-(4-(((1-((4-Nitrophenyl)sulfonyl)-1H-1,2,3-triazol-4-yl)methyl)piperazin-1-yl)-2H-benzo[*b*][1,4]thiazine 1,1-dioxide (8f). Yellow solid; M.p: 169–171 °C; ¹H-NMR (500 MHz, CDCl₃) δ 8.48 (d, *J* = 8.0 Hz, 2H), 8.25 (d, *J* = 8.0 Hz, 2H), 8.13 (s, 1H, tri-H), 7.92 (d, *J* = 8.0 Hz, 1H), 7.73 (d, *J* = 8.0 Hz, 1H), 7.64–7.60 (m, 1H), 7.44–7.39 (m, 1H), 5.28 (s, 2H, N-CH₂), 4.38 (s, 2H, SO₂-CH₂), 3.79 (t, *J* = 4.0 Hz, 4H, 2N-CH₂), 3.56 (t, *J* = 4.0 Hz, 4H, 2N-CH₂). ¹³C-NMR (126 MHz, CDCl₃): δ 153.22, 147.29, 146.19, 142.33, 135.33, 133.46, 132.17, 130.28, 129.72, 127.67 (2C), 124.34, 122.63 (2C), 122.10, 59.77, 49.74, 46.68 (2C), 44.13 (2C). ESI-MS: 532.09 [*M* + *H*]. Anal. calcd for C₂₁H₂₁N₇O₆S₂: C, 47.45; H, 3.98; N, 18.44. Found: C, 47.41; H, 3.95; N, 18.46.

4-(((4-((1,1-Dioxido-2H-benzo[*b*][1,4]thiazin-3-yl)piperazin-1-yl)methyl)-1H-1,2,3-triazol-1-yl)sulfonyl)benzonitrile (8g). White solid; M.p: 159–161 °C; ¹H-NMR (500 MHz, CDCl₃) δ 8.03 (s, 1H, tri-H), 7.91 (d, *J* = 8.0 Hz, 1H), 7.81 (d, *J* = 8.0 Hz, 2H), 7.72 (d, *J* = 8.0 Hz, 1H), 7.63–7.58 (m, 1H), 7.50 (d, *J* = 8.0 Hz, 2H), 7.41–7.36 (m, 1H), 5.26 (s, 2H, N-CH₂), 4.35 (s, 2H, SO₂-CH₂), 3.77 (t, *J* = 4.0 Hz, 4H, 2N-CH₂), 3.56 (t, *J* = 4.0 Hz, 4H, 2N-CH₂). ¹³C-NMR (126 MHz, CDCl₃): δ 153.49, 146.35, 145.13, 135.40, 133.43(2C), 132.18, 131.05, 129.93, 129.22, 127.33(2C), 124.42, 122.78, 120.58, 119.18, 59.74, 49.31, 46.78(2C), 44.33(2C). ESI-MS: 512.10 [*M* + *H*]. Anal. calcd for C₂₂H₂₁N₇O₄S₂: C, 51.65; H, 4.14; N, 19.17. Found: C, 51.69; H, 4.11; N, 19.14.

Minimum inhibitory concentration (MIC) of the synthesized compounds was determined by broth dilution method according to the Clinical and Laboratory Standards Institute (CLSI) guidelines. Separately, each stock solution of the compounds synthesized was prepared in 1.5 mL of dimethylsulphoxide (DMSO) to achieve final concentration of 64 µg mL⁻¹. The serial dilutions from the stock was made in 96-well microplates using Mueller–Hinton broth (Becton Dickinson, Sparks, MD, USA) to obtain the different concentrations of the test compounds ranging from 32 µg mL⁻¹ to 0.25 µg mL⁻¹. The *Staphylococcus aureus* mutant strain suspension (Approx. 5 × 10⁵ colony-forming units mL⁻¹) was prepared from 24 h fresh culture. Of about 100 µL of this culture was transferred each well of the 96 well plate that contain different concentrations of synthesized compounds and incubated at 37 °C for 24 h. Approximately 40 µL 0.4 µg mL⁻¹ solution of resazurin (microbial growth indicator) was added to each well of the plate maintained at 37 °C for 30 min. The MIC values visually evaluated. The lowest concentration of synthesized compounds exhibit no visible

growth was noted as the MIC of that compound. The experiment was conducted in triplicate.

Measurement of hemolytic activity

The hemolytic activity of the **6e**, **6f**, **6g**, **6i**, **8d**, **8e** was assayed against human red blood cells (hRBCs) by measuring the amount of hemoglobin released after treatment. The hRBCs, freshly collected from a healthy volunteer in polycarbonate tubes containing heparin, were washed three times in sterile phosphate-buffered saline (PBS) and centrifuged at 2000×*g* for 5 min or until the supernatant became clear. The hRBCs were diluted to a final concentration of 2% (vol/vol), then 50 µL of the hRBCs suspension was incubated with 50 µL of different concentrations (0.75 to 100 µg mL⁻¹) of the tested compounds dissolved in PBS. After 1 h of incubation at 37 °C, intact hRBCs were pelleted by centrifugation at 2000×*g* for 10 min. The supernatant was transferred to a new 96-well plate and the release of hemoglobin was monitored by measurement of absorbance at 405 nm using a Multiskan FC microplate reader. The hRBCs in PBS only (OD_{Blank}) and in 0.1% Triton X-100 (OD_{Triton X-100}) were employed as negative (0% hemolysis) and positive (100% hemolysis) controls, respectively. The percentage of hemolysis was calculated according to the following equation:

$$\% \text{ Hemolysis} = (\text{OD}_{\text{Sample}} - \text{A}_{\text{Blank}}) / (\text{OD}_{\text{TritonX-100}} - \text{OD}_{\text{Blank}}) \times 100$$

Molecular docking studies

Docking simulation were performed by using AutoDock VINA integrated in the PyRx 0.8 virtual screening tool to identify compounds with high binding affinity.^{36,37} *In silico* docking studies to evaluate the molecular interaction profile and binding affinity variations of **6e**, **6f**, **6g**, **6i**, **8d**, **8e** compounds were done with the Human, Mouse and Bovine Toll-like receptor (TLR4) proteins with PDB ID's 3FXI, 3VQ1, 3RG1 respectively. Protein structures were processed to ensure an optimized structure for docking studies and it was executed with UCSF Chimera Dock Prep module and that includes the following steps: elimination of water molecules and other ligands, addition of missing atoms and residues, energy minimization and assigning charges and polar hydrogens and then converted to the pdbqt format. The 2D structure of the ligands was drawn with ChemDraw software and the structures were optimized through energy minimization with MMFF94 force field parameters and conjugate gradient algorithm using Open Babel module of PyRx and eventually converted the ligands to the AutoDock compatible pdbqt format to carry out docking exploration. Post docking analysis and visualization of binding poses and molecular interactions were done with BIOVIA Discovery Studio 2021 and Chimera X tools.

Binding energies and molecular interaction profile of the compounds were compared with the Human, Mouse and Bovine TLR4 proteins. Autodock Vina grid box was created around the whole protein in 3FXI, 3VQ1 and 3RG1 proteins with the following details of the vina search space. Binding affinity



outcomes of compounds from the docking assessments are as follows.

	3FXI	3VQ1	3RG1
Centre (Å)			
x	3.2577	7.6491	−1.8714
y	4.7519	18.7324	−8.9592
z	21.6834	28.9341	−0.9964
Dimensions (Å)			
x	74.3523	90.9402	81.4867
y	87.0448	106.1912	92.6772
z	97.1752	88.0768	95.9081

Conflicts of interest

The authors declare no conflict of interest.

Acknowledgements

The authors are thankful to the director, NIT-Warangal for providing characterization data ($^1\text{H-NMR}$, $^{13}\text{C-NMR}$ and mass) of newly synthesized compounds.

References

- 1 C. Opoku-Temeng, G. A. Naclerio, H. Mohammad, N. Dayal, N. S. Abutaleb, M. N. Seleem and H. O. Sintim, *Eur. J. Med. Chem.*, 2018, **155**, 797–980.
- 2 M. G. Page and K. Bush, *Curr. Opin. Pharmacol.*, 2014, **18**, 91–97.
- 3 S. Bhargava, P. Singla, A. Manocha, M. Kankra, A. Sharma, A. Ahirwar, R. Ralhan, U. Thapliyal and P. Mehra, *Indian J. Clin. Biochem.*, 2020, **35**(2), 232–238.
- 4 G. Lippi, G. L. Salvagno, M. Montagnana, G. Brocco and G. C. Guidi, *Clin. Chem. Lab. Med.*, 2006, **44**(3), 311–316.
- 5 A.-M. Simundic, G. Baird, J. Cadamuro, S. J. Costelloe and G. Lippi, *Crit. Rev. Clin. Lab. Sci.*, 2020, **57**(1), 1–21.
- 6 W. N. W. Azman, J. Omar, T. S. Koon and T. S. T. Ismail, *Oman Med. J.*, 2019, **34**(2), 94–98.
- 7 O. Sonntag, *J. Clin. Chem. Clin. Biochem.*, 1986, **24**(2), 127–139.
- 8 I. Minović, L. D. Dikkeschei, M. J. Vos and J. E. Kootstra-Ros, *Ann. Lab. Med.*, 2021, **41**(5), 485–488.
- 9 L. Heireman, P. V. Geel, L. Musger, E. Heylen, W. Uyttenbroeck and B. Mahieu, *Clin. Biochem.*, 2017, **50**(18), 1317–1322.
- 10 T. Teixeira, S. L. Kweder and A. Saint-Raymond, *Clin. Pharmacol. Ther.*, 2020, **107**(3), 507–513.
- 11 L. Chen, W. Fu, L. Zheng, Y. Wang and G. Liang, *Drug Discovery Today*, 2018, **23**, 1187–1202.
- 12 E. Vacchelli, L. Galluzzi, A. Eggermont, W. H. Fridman, J. Galon, C. Sautes-Fridman, E. Tartour, L. Zitvogel and G. Kroemer, *Oncoimmunology*, 2012, **1**, 894–907.
- 13 D. Dheer, V. Singh and R. Shankar, *Bioorg. Chem.*, 2017, **71**, 30–54.
- 14 K. Bozorov, J. Zhao and H. A. Aisa, *Bioorg. Med. Chem.*, 2019, **27**, 3511–3531.
- 15 R. Gondru, S. Kanugala, S. Raj, C. G. Kumar, M. Pasupuleti, J. Banothu and R. Bavantula, *Bioorg. Med. Chem. Lett.*, 2021, **33**, 127746.
- 16 K. S. Kumar, P. K. Naikawadi, R. Jatoth and R. Dandela, *Org. Biomol. Chem.*, 2019, **17**, 7320–7324.
- 17 (a) B. Zhang, *Eur. J. Med. Chem.*, 2019, **168**, 357–372; (b) C. Deng, H. Yan, J. Wang, K. Liu, B.-S. Liu and Y.-M. Shi, *Eur. J. Med. Chem.*, 2022, **244**, 114888; (c) K. E. Gadali, M. Rafya, A. E. Mansouri, M. Maatallah, A. Van-der lee, A. Mehdi, A. Ouahrouch, F. Benkhalti, Y. S. Sanghvi, M. Taourirte and H. B. Lazrek, *J. Mol. Struct.*, 2023, **1282**, 135179; (d) K. Rasoolijokari, P. Salehi, A. Aliahmadi, B. Heidari and M. Bararjanian, *Phytochem. Lett.*, 2023, **54**, 23–27.
- 18 I. S. Bennet, G. Brooks, N. J. P. Broom, S. H. Calvert, K. Coleman and I. Francois, *J. Antibiot.*, 1991, **44**, 969–978.
- 19 G. A. Stilwell, H. G. Adams and M. Turck, *Antimicrob. Agents Chemother.*, 1975, **8**, 751–753.
- 20 (a) E. N. Prilezhaeva, *Russ. Chem. Rev.*, 2000, **69**, 367–408; (b) O. Vorasin, K. Momphanao, P. Katrun, C. Kuhakarn and C. Jiarpinitnun, *Bioorg. Med. Chem. Lett.*, 2022, **63**, 128652.
- 21 Z. Jin, P. C. Vandort and P. L. Fuchs, *Phosphorus, Sulfur Silicon*, 1994, **95**, 1–19.
- 22 M. Mikolajczyk, *Tetrahedron*, 1986, **42**, 5459–5495.
- 23 G. Andrew, F. Ian, L. Andrew, P. Andrew, W. Graham and G. Vincenzo, European Patent EP, 1511727, 2007.
- 24 N. Ramu, T. M. Krishna, V. Nasipireddy, R. Kapavarapu and S. Narsimha, *ChemistrySelect*, 2023, **8**, e202300777.
- 25 E. R. Sucharitha, T. M. Krishna, R. Manchal, G. Ramesh and S. Narsimha, *Bioorg. Med. Chem. Lett.*, 2021, **47**, 128201.
- 26 V. R. Dodlapati, T. M. Reddy, M. Azam, K. Min and S. Narsimha, *ChemistrySelect*, 2023, **8**, e202301834.
- 27 E. R. Sucharitha, S. K. Nukala, N. S. Thirukovela, R. Palabindela, R. Sreerama and S. Narsimha, *ChemistrySelect*, 2023, **8**, e202204256.
- 28 N. M. Kumar, S. K. Nukala, T. N. Swamy, M. Ravinder, T. M. Krishna and S. Narsimha, *J. Mol. Struct.*, 2022, **1250**, 131722.
- 29 N. M. Kumar, S. K. Nukala, N. S. Thirukovela, R. Sreerama, E. R. Sucharitha, P. Kamarajugadda and S. Narsimha, *J. Mol. Struct.*, 2022, **1262**, 132975.
- 30 S. Narsimha, K. S. Battula, Y. N. Reddy and V. R. Nagavelli, *Chem. Heterocycl. Compd.*, 2018, **54**(12), 1161–1167.
- 31 R. Sreerama, T. N. Swamy, M. Ravinder, N. V. Reddy and S. Narsimha, *Phosphorus, Sulfur Silicon*, 2020, **196**, 455–460.
- 32 R. Sreerama, N. M. Kumar, S. K. Nukala, E. R. Sucharitha, H. R. Babu and S. Narsimha, *Russ. J. Gen. Chem.*, 2021, **91**(12), 2515–2521.
- 33 V. R. Nagavelli, S. K. Nukala, S. Narsimha, K. S. Battula, S. J. Tangeda and Y. N. Reddy, *Med. Chem. Res.*, 2016, **25**, 1781–1793.
- 34 A. Oddo and P. R. Hansen, *Methods Mol. Biol.*, 2017, **1548**, 427–435.
- 35 A. Daina, O. Michielin and V. Zoete, *Sci. Rep.*, 2017, **7**, 42717.
- 36 S. Dallakyan and A. J. Olson, *Chem. Biol.*, 2014, **1263**, 243–250.
- 37 Z. Zhu, Z. Rahman, M. Aamir, S. Z. A. Shah, S. Hamid, A. Bilawal, S. Lie and M. Ishfaq, *RSC Adv.*, 2023, **13**, 2057.

